News/ News/ Oncology BMS gets FDA OK for first LAG-3 checkpoint inhibitor Phil Taylor Bristol-Myers Squibb, favezelimab, LAG-3, Merck & Co, Opdivo, Opdualag, regulatory approval, relatlimab 0 Comment Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer Share X BMS gets FDA OK for first LAG-3 checkpoint inhibitor https://pharmaphorum.com/news/bms-gets-fda-ok-for-first-lag-3-checkpoint-inhibitor/